Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
According to the recent report using EGFR tyrosine kinase inhibitors (EGFR-TKI), there is all over survival of the EGFR gene mutation-positive NSCLC in a tendency to extension. However, the real situation and the reason are not clarified.This observational study collects the data of EGFR gene mutation-positive NSCLC approximately 2,000 from the medical record of approximately 20 facilities in Japan and observes the treatment reality of EGFR gene mutation-positive NSCLC.
Overall survival of the patients. [ Time Frame: Up to 3 monthes. Data will be collected retrospectively from medical records.Survival status as of the end of December 2014, date of death or date of last follow-up of survival. ]
Secondary Outcome Measures
Overall survival by patient background [ Time Frame: Up to 3 monthes. Data will be collected retrospectively from medical records. ]
Overall survival by treatment sequence [ Time Frame: Up to 3 monthes. Data will be collected retrospectively from medical records. ]
Treatment time by treatment category [ Time Frame: Up to 3 monthes. Data will be collected retrospectively from medical records. ]
Time to Treatment Failure (TTF) of Gefitinib treatment [ Time Frame: Up to 3 monthes. Data will be collected retrospectively from medical records. ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Approximately 2000, Advanced Non Small Cell Lung cancer (aNSCLC) patients who fulfil the inclusion/exclusion criteria will be recruited by 10 to 20 investigational sites in Japan.
1. EGFR mutation-positive progress recurrent non-small cell lung cancer subject.
2. Subjects who commenced on first-line treatment between January, 2008 and December 2012.
1. Patients has a treatment history with the drug which was not approved for marketing authorization as of 31th December , 2014
2. Person who were planning and/or getting involved in this survey. (applies to both AstraZeneca staff and/or staff at the study site)
3. Previous enrolment in the present study.
4. Patient was not evaluated to be appropriate for study enrolment by the investigators